Plain-English translation of NCT06397703 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining hormone-blocking medications like Degarelix, Leuprolide, or Relugolix with a specialized radiation therapy called SBRT (stereotactic body radiation therapy) works better than SBRT alone for men with intermediate-risk prostate cancer. You'll be able to choose which treatment group you join—one receiving both the medication and radiation, or radiation therapy by itself. Both groups will be followed closely for up to five years to see how well their cancer is controlled.
Doctors aren't sure whether adding hormone therapy to this newer, faster type of radiation therapy actually improves outcomes for men with this specific type of prostate cancer, or whether the radiation alone is just as effective. This trial will help answer that question so future patients get the best possible treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll choose which arm to enter. In the hormone-plus-radiation group, you'll receive monthly or daily hormone-blocking medication for six months, starting with three months before your radiation begins. Both groups will then receive five radiation treatments given every other day over about two weeks. After that, you'll have follow-up visits every six months for five years, including a prostate biopsy around 24-30 months to check how well the cancer was controlled. After two years, some follow-ups can be done by phone or chart review instead of in-person visits.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States